

Devolved Administrations



Introduction

Introduction

The [Department of Health's AcoRD guidance \(2013\)](#) provides a framework for the NHS and its partners to identify, attribute and recover the various costs associated with research in the NHS in a transparent, robust and consistent manner.

Through this short module we will explore the way AcoRD guidance is applied to commercial and non-commercial research, the categories of research activities described in the AcoRD guidance, how the costs associated with these categories should be met, and the social arrangements for charity-funded research.

We will explore the key principles through real life examples, and you will have the opportunity to test your own knowledge through scenario based questions.



Please note that whilst this module refers to arrangements in England only, the principles of AcoRD have been agreed across all UK countries. Northern Ireland, Scotland and Wales each have an AcoRD policy which reflects the infrastructure in their respective countries.

At key points within the module, where appropriate, arrangements in the Devolved Administration will be referred to. These policies below provide further information:

[Wales](#)

[Scotland](#)

Commercial and Non-Commercial Studies

Commercial


Non-Commercial

Contracts

A key principle of the Department of Health guidance is that the NHS bears the cost of treating its patients, even if the treatment is experimental.

This applies to both commercial and non-commercial research, though there are different arrangements for the costs of the research.


It is essential that both the NHS and its partner organisations identify and quantify the full cost of non-commercial research and reach a shared understanding of how these costs are recovered through appropriate funding arrangements, to avoid studies being underfunded.



In Wales, any study adopted onto the NIHR portfolio is also included on the National Institute for Social Care and Health Research (NISCHR) portfolio. If you are a Chief Investigator whose research study's lead site is in Wales, please contact your R&D office for advice on the adoption process.

In Scotland studies adopted onto the portfolio of another UK nation are automatically eligible for support by NHS Research Scotland (NRS). If the study is led from Scotland and funded by an eligible funder (see [NRS Funding Guidance Annex 2 Eligible Funders](#)) it is also automatically eligible for support by NRS.

Studies which are funded by overseas governments/charities, or funded by commercial companies but sponsored by a non-commercial organisation may be considered for adoption through the process detailed in the [Funding Guidance Annex 3 SOP for Adoption](#)



Treatment Costs

To apply for the Excess Treatment Costs for your study, please contact XXX

In Wales, a central budget is held for Excess Treatment Costs - please see the link for details of the application process:

<http://www.wales.nhs.uk/sites3/page.cfm?orgid=952&pid=52113>

For more information on the process for applying for a subvention for high Excess Treatment Costs in Scotland see

<http://www.cso.scot.nhs.uk/index.php/nrs/nrs-funding-2/excess-treatment-costs-for-research>

Service Support Costs

In Wales, NHS support costs are allocated by NISCHR to NHS Organisations, in addition to existing infrastructure support that is in place. Please ensure that you contact your R&D office at the earliest opportunity to discuss the resources required to deliver your study.

Research Costs

Under these circumstances, the cost of the activities in Part B will be met by the Department of Health. Equivalent arrangements are in place in the Devolved Administrations - please see the links already provided in this document and contact your local R&D office for advice. Research Part B Costs include:

- Local study trial co-ordination and management.
- Data collection needed to answer the questions that the research study is addressing (including collecting data for and completing the report).
- Regulatory preparation and compliance including obtaining ethical approval and complying with the Medicine for Human Use (Clinical Trials) Regulations 2004.
- The time taken by Chief and Principal Investigators (CI and PI) to explain the study to professional colleagues, and to understand, the research elements of a study. For example the time taken to explain the criteria for patient eligibility or to explain the randomisation protocol.

A list of common research activities attributed as Research Costs, Part A and B can be found in Annex A of the AcoRD Guidance.

Please follow the links below for the country-specific Annexes:

[Wales](#)

[Scotland](#)



If you are leading your study from Wales, the NHS costs are met by NISCHR. Please see the following link for more information:
<http://www.wales.nhs.uk/sites3/page.cfm?orgid=952&pid=60391>

Please contact your local R&D office advice about how to access the resources required to deliver your study.

If your study is led from Scotland, the NHS Support and Part B Research Costs are met by NRS funding allocated to NHS Boards. Please contact your local R&D office advice about how to access the resources required to deliver your study.

In Scotland funding is allocated to NHS Boards in the form of NRS Support Costs and NRS Infrastructure to support activities identified as NHS Support Costs. Please ensure that you contact your local R&D office at the earliest opportunity to discuss the resources required to deliver your study.

Scenario Questions

A list of 'Frequently Asked Questions' is also provided in Annex B of the AcoRD guidance. Devolved Administration country-specific Annex B:

[Wales](#)

[Scotland](#)